Edition:
United States

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

4.00USD
9 Dec 2016
Change (% chg)

$-0.12 (-2.91%)
Prev Close
$4.12
Open
$4.10
Day's High
$4.27
Day's Low
$4.00
Volume
13,113
Avg. Vol
55,533
52-wk High
$9.72
52-wk Low
$3.21

CYCC.OQ

Chart for CYCC.OQ

About

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor... (more)

Overall

Beta: 3.16
Market Cap(Mil.): $17.00
Shares Outstanding(Mil.): 4.25
Dividend: --
Yield (%): --

Financials

  CYCC.OQ Industry Sector
P/E (TTM): -- 41.98 30.40
EPS (TTM): -4.08 -- --
ROI: -63.42 -0.36 15.24
ROE: -65.01 -0.94 16.58

BRIEF-Cyclacel Pharmaceuticals Q3 loss per share $0.86

* Cyclacel pharmaceuticals reports 3rd quarter 2016 financial results

Nov 14 2016

BRIEF-Intra-Cellular Therapies reports Q3 financial results

* Intra-Cellular Therapies reports third quarter 2016 financial results and provides corporate update

Nov 09 2016

BRIEF-Tang Capital reports 9.5 pct stake in Cyclacel Pharmaceuticals

Source text - http://bit.ly/2cDs1vi Further company coverage:

Sep 16 2016

BRIEF-Intra-Cellular Therapies files for mixed shelf of up to $350 mln

* Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2c1aXOy) Further company coverage:

Sep 02 2016

BRIEF-Intra-Cellular Therapies reported Q2 EPS ($0.71)

* Cellular Therapies reports second quarter 2016 financial results and provides corporate update

Aug 04 2016

BRIEF-Cyclacel Pharmaceuticals may issue, sell shares having aggregate offering price of up to $4 mln through FBR

* Sales agreement with FBR Capital Markets & Co; may issue, sell shares having aggregate offering price of up to $4 million through FBR Source text: http://1.usa.gov/28Qcw2y Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 23 2016

Competitors

Earnings vs. Estimates